Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 4873089, 13 pages
http://dx.doi.org/10.1155/2016/4873089
Review Article

Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?

Translational Oncology Division, OncoHealth Institute, Health Research Institute, University Hospital Fundación Jiménez Díaz-UAM, Madrid, Spain

Received 9 June 2016; Revised 28 July 2016; Accepted 3 August 2016

Academic Editor: Hanlin L. Wang

Copyright © 2016 Javier Martinez-Useros and Jesus Garcia-Foncillas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Raimondi, P. Maisonneuve, and A. B. Lowenfels, “Epidemiology of pancreatic cancer: an overview,” Nature Reviews Gastroenterology and Hepatology, vol. 6, no. 12, pp. 699–708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Egawa, K. Takeda, S. Fukuyama, F. Motoi, M. Sunamura, and S. Matsuno, “Clinicopathological aspects of small pancreatic cancer,” Pancreas, vol. 28, no. 3, pp. 235–240, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Ariyama, M. Suyama, K. Satoh, and J. Sai, “Imaging of small pancreatic ductal adenocarcinoma,” Pancreas, vol. 16, no. 3, pp. 396–401, 1998. View at Google Scholar
  6. D. P. Kelsen, R. Portenoy, H. Thaler, Y. Tao, and M. Brennan, “Pain as a predictor of outcome in patients with operable pancreatic carcinoma,” Surgery, vol. 122, no. 1, pp. 53–59, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Blackford, G. Parmigiani, T. W. Kensler et al., “Genetic mutations associated with cigarette smoking in pancreatic cancer,” Cancer Research, vol. 69, no. 8, pp. 3681–3688, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Lin, A. Tamakoshi, T. Kawamura et al., “A prospective cohort study of cigarette smoking and pancreatic cancer in Japan,” Cancer Causes and Control, vol. 13, no. 3, pp. 249–254, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. A. B. Lowenfels, P. Maisonneuve, G. Cavallini et al., “Pancreatitis and the risk of pancreatic cancer,” The New England Journal of Medicine, vol. 328, no. 20, pp. 1433–1437, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. S. T. Chari, C. L. Leibson, K. G. Rabe et al., “Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer,” Gastroenterology, vol. 134, no. 1, pp. 95–101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. X.-Z. Chen, R. Wang, H.-N. Chen, and J.-K. Hu, “Cytotoxin-associated gene A-negative strains of Helicobacter pylori as a potential risk factor of pancreatic cancer: a meta-analysis based on nested case-control studies,” Pancreas, vol. 44, no. 8, pp. 1340–1344, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Venerito, R. Vasapolli, T. Rokkas, and P. Malfertheiner, “Helicobacter pylori and gastrointestinal malignancies,” Helicobacter, vol. 20, supplement 1, pp. 36–39, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Manuel, “Pancreatic cancer,” The New England Journal of Medicine, vol. 362, no. 17, pp. 1562–1617, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Stathis and M. J. Moore, “Advanced pancreatic carcinoma: current treatment and future challenges,” Nature Reviews Clinical Oncology, vol. 7, no. 3, pp. 163–172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. V. Fong and J. M. Winter, “Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive,” Cancer Journal, vol. 18, no. 6, pp. 530–538, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. D. N. Reddy, P. V. Sriram, G. Das, and G. V. Rao, “Endoscopic treatment of pancreatic disorders,” Tropical Gastroenterology, vol. 22, no. 3, pp. 149–154, 2001. View at Google Scholar · View at Scopus
  17. Q. Wang, Q. Ding, Z. Dong, R. A. Ehlers, and B. M. Evers, “Downregulation of mitogen-activated protein kinases in human colon cancers,” Anticancer Research, vol. 20, no. 1, pp. 75–83, 2000. View at Google Scholar · View at Scopus
  18. K. Strimbu and J. A. Tavel, “What are biomarkers?” Current Opinion in HIV & AIDS, vol. 5, no. 6, pp. 463–466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Louvet, R. Labianca, P. Hammel et al., “Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3509–3516, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Van Cutsem, H. van de Velde, P. Karasek et al., “Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer,” Journal of Clinical Oncology, vol. 22, no. 8, pp. 1430–1438, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Vivaldi, C. Caparello, G. Musettini et al., “First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: patients' outcome and analysis of prognostic factors,” International Journal of Cancer, vol. 139, no. 4, pp. 938–945, 2016. View at Publisher · View at Google Scholar
  22. C. M. Kang, J. Y. Kim, G. H. Choi et al., “The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer,” Journal of Surgical Research, vol. 140, no. 1, pp. 31–35, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. S. K. Maithel, S. Maloney, C. Winston et al., “Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma,” Annals of Surgical Oncology, vol. 15, no. 12, pp. 3512–3520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. F. J. F. Engelken, V. Bettschart, M. Q. Rahman, R. W. Parks, and O. J. Garden, “Prognostic factors in the palliation of pancreatic cancer,” European Journal of Surgical Oncology, vol. 29, no. 4, pp. 368–373, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. J. S. Falconer, K. C. H. Fearon, J. A. Ross et al., “Acute-phase protein response and survival duration of patients with pancreatic cancer,” Cancer, vol. 75, no. 8, pp. 2077–2082, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. N. B. Jamieson, P. Glen, D. C. McMillan et al., “Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas,” British Journal of Cancer, vol. 92, no. 1, pp. 21–23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. J. K. Pine, K. G. Fusai, R. Young et al., “Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas,” European Journal of Surgical Oncology, vol. 35, no. 6, pp. 605–610, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Mitsunaga, M. Ikeda, S. Shimizu et al., “C-reactive protein level is an indicator of the aggressiveness of advanced pancreatic cancer,” Pancreas, vol. 45, no. 1, pp. 110–116, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. J. R. Infante, H. Matsubayashi, N. Sato et al., “Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma,” Journal of Clinical Oncology, vol. 25, no. 3, pp. 319–325, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Gundewar, A. Sasor, K. S. Hilmersson, R. Andersson, and D. Ansari, “The role of SPARC expression in pancreatic cancer progression and patient survival,” Scandinavian Journal of Gastroenterology, vol. 50, no. 9, pp. 1170–1174, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Sinn, B. V. Sinn, J. K. Striefler et al., “SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study,” Annals of Oncology, vol. 25, no. 5, pp. 1025–1032, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. S. H. Shin, S. C. Kim, S.-M. Hong et al., “Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival,” Pancreas, vol. 42, no. 2, pp. 216–222, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Bournet, F. Muscari, C. Buscail et al., “KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma,” Clinical and Translational Gastroenterology, vol. 7, article e157, 2016. View at Publisher · View at Google Scholar
  34. K. Tjensvoll, M. Lapin, T. Buhl et al., “Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer,” Molecular Oncology, vol. 10, no. 4, pp. 635–643, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Kinugasa, K. Nouso, K. Miyahara et al., “Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer,” Cancer, vol. 121, no. 13, pp. 2271–2280, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. J. A. DiGiuseppe, R. H. Hruban, S. N. Goodman et al., “Overexpression of p53 protein in adenocarcinoma of the pancreas,” American Journal of Clinical Pathology, vol. 101, no. 6, pp. 684–688, 1994. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Mäkinen, T. Hakala, P. Lipponen, E. Alhava, and M. Eskelinen, “Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma,” Anticancer Research, vol. 18, no. 1, pp. 615–618, 1998. View at Google Scholar · View at Scopus
  38. Y. Nio, M. Dong, C. Iguchi et al., “Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy,” Journal of Surgical Oncology, vol. 76, no. 3, pp. 188–196, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Gerdes, A. Ramaswamy, A. Ziegler et al., “p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb,” Annals of Surgery, vol. 235, no. 1, pp. 51–59, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Jeong, Y. N. Park, J. S. Park, D.-S. Yoon, H. S. Chi, and B. R. Kim, “Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer,” Yonsei Medical Journal, vol. 46, no. 4, pp. 519–525, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. R. J. Bold, K. R. Hess, A. S. Pearson et al., “Prognostic factors in resectable pancreatic cancer: p53 and Bcl-2,” Journal of Gastrointestinal Surgery, vol. 3, no. 3, pp. 263–277, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Lundin, S. Nordling, K. Von Boguslawsky, P. J. Roberts, and C. Haglund, “Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer,” Anticancer Research, vol. 15, no. 6B, pp. 2659–2668, 1995. View at Google Scholar · View at Scopus
  43. H. Kim, C. Y. Park, J. H. Lee, J. C. Kim, C. K. Cho, and H. J. Kim, “Ki-67 and p53 expression as a predictive marker for early postoperative recurrence in pancreatic head cancer,” Annals of Surgical Treatment and Research, vol. 88, no. 4, pp. 200–207, 2015. View at Publisher · View at Google Scholar
  44. Ö. Sagol, T. Yavuzşen, I. Öztop et al., “The effect of apoptotic activity, survivin, Ki-67, and P-glycoprotein expression on prognosis in pancreatic carcinoma,” Pancreas, vol. 30, no. 4, pp. 343–348, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. K. J. Stanton, R. A. Sidner, G. A. Miller et al., “Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas,” American Journal of Surgery, vol. 186, no. 5, pp. 486–492, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Friess, Z. Lu, H. U. Graber et al., “Bax, but not bcl-2, influences the prognosis of human pancreatic cancer,” Gut, vol. 43, no. 3, pp. 414–421, 1998. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Naka, M. Kobayashi, K. Ashida, N. Toyota, T. Kaneko, and N. Kaibara, “Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer,” International Journal of Oncology, vol. 12, no. 5, pp. 1111–1116, 1998. View at Google Scholar
  48. Y.-X. Hu, H. Watanabe, K. Ohtsubo et al., “Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma,” Clinical Cancer Research, vol. 3, no. 9, pp. 1473–1477, 1997. View at Google Scholar · View at Scopus
  49. K. Ohtsubo, H. Watanabe, Y. Yamaguchi et al., “Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters,” Journal of Gastroenterology, vol. 38, no. 7, pp. 663–671, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Tascilar, H. G. Skinner, C. Rosty et al., “The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma,” Clinical Cancer Research, vol. 7, no. 12, pp. 4115–4121, 2001. View at Google Scholar · View at Scopus
  51. A. V. Biankin, A. L. Morey, C.-S. Lee et al., “DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma,” Journal of Clinical Oncology, vol. 20, no. 23, pp. 4531–4542, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. K. M. Murphy, K. A. Brune, C. Griffin et al., “Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%,” Cancer Research, vol. 62, no. 13, pp. 3789–3793, 2002. View at Google Scholar · View at Scopus
  53. K. Khan, D. Cunningham, C. Peckitt et al., “miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial,” Oncotarget, vol. 7, no. 11, pp. 12672–12681, 2016. View at Publisher · View at Google Scholar
  54. N. Habbe, J.-B. M. Koorstra, J. T. Mendell et al., “MicroRNA miR-155 is a biomarker of early pancreatic neoplasia,” Cancer Biology and Therapy, vol. 8, no. 4, pp. 340–346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. Z. Xie, X. Chen, J. Li et al., “Salivary HOTAIR and PVT1 as novel biomarkers for early pancreatic cancer,” Oncotarget, vol. 23, article 8323, 2016. View at Publisher · View at Google Scholar
  56. J. Martinez-Useros, T. Georgiev-Hristov, A. Borrero-Palacios et al., “Identification of poor-outcome biliopancreatic carcinoma patients with two-marker signature based on ATF6α and p-p38 ‘sTARD compliant’,” Medicine, vol. 94, no. 45, Article ID e1972, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. Z. Niu, M. Wang, L. Zhou, L. Yao, Q. Liao, and Y. Zhao, “Elevated GRP78 expression is associated with poor prognosis in patients with pancreatic cancer,” Scientific Reports, vol. 5, Article ID 16067, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. A. Handra-Luca, S.-M. Hong, K. Walter, C. Wolfgang, R. Hruban, and M. Goggins, “Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas,” British Journal of Cancer, vol. 104, no. 8, pp. 1296–1302, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. Y.-J. Li and X.-R. Ji, “Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer,” World Journal of Gastroenterology, vol. 9, no. 2, pp. 368–372, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. S.-M. Hong, A. Li, K. Olino et al., “Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas,” Modern Pathology, vol. 24, no. 9, pp. 1237–1247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. M. M. Oken, R. H. Creech, D. C. Tormey et al., “Toxicity and response criteria of the Eastern Cooperative Oncology Group,” American Journal of Clinical Oncology, vol. 5, no. 6, pp. 649–655, 1982. View at Google Scholar · View at Scopus
  62. K. S. Goonetilleke and A. K. Siriwardena, “Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer,” European Journal of Surgical Oncology, vol. 33, no. 3, pp. 266–270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. F. T. Bosman, F. Carneiro, R. H. Hruban, and N. D. Theise, Eds., World Health Organization Classification of Tumours of the Digestive System, IARC Press, Lyon, France, 2010.
  64. G. H. R. Klöppel, D. S. Longnecker, G. Adler, S. E. Kern, and T. J. Partanen, Ductal Adenocarcinoma of the Pancreas, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System, IARC Press, Lyon, France, 2000.
  65. J.-E. Kim, K. T. Lee, J. K. Lee, S. W. Paik, J. C. Rhee, and K. W. Choi, “Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population,” Journal of Gastroenterology and Hepatology, vol. 19, no. 2, pp. 182–186, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Kawai, K. Suzuki, K. Nishio et al., “Smoking and serum CA19-9 levels according to Lewis and secretor genotypes,” International Journal of Cancer, vol. 123, no. 12, pp. 2880–2884, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. M. J. Duffy, C. Sturgeon, R. Lamerz et al., “Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report,” Annals of Oncology, vol. 21, no. 3, pp. 441–447, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. D. Basso, C. Fabris, A. Meani et al., “C reactive protein in pancreatic cancer and chronic pancreatitis,” Annals of Clinical Research, vol. 20, no. 6, pp. 414–416, 1988. View at Google Scholar · View at Scopus
  69. J. Szkandera, M. Stotz, G. Absenger et al., “Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients,” British Journal of Cancer, vol. 110, no. 1, pp. 183–188, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Haruki, H. Shiba, Y. Shirai et al., “The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection,” World Journal of Surgery, vol. 2016, article 8, 2016. View at Publisher · View at Google Scholar
  71. W. Han, F. Cao, M.-B. Chen et al., “Prognostic value of SPARC in patients with pancreatic cancer: a systematic review and meta-Analysis,” PLoS ONE, vol. 11, article e0145803, 2016. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Vaz, D. Ansari, A. Sasor, and R. Andersson, “SPARC: a potential prognostic and therapeutic target in pancreatic cancer,” Pancreas, vol. 44, no. 7, pp. 1024–1035, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. S. P. Thayer, M. P. di Magliano, P. W. Heiser et al., “Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis,” Nature, vol. 425, no. 6960, pp. 851–856, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. M. P. Di Magliano, S. Sekine, A. Ermilov, J. Ferris, A. A. Dlugosz, and M. Hebrok, “Hedgehog/Ras interactions regulate early stages of pancreatic cancer,” Genes and Development, vol. 20, no. 22, pp. 3161–3173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Barceló, J. Etchin, M. R. Mansour et al., “Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells,” Gastroenterology, vol. 147, no. 4, pp. 882–892.e8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Almoguera, D. Shibata, K. Forrester, J. Martin, N. Arnheim, and M. Perucho, “Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes,” Cell, vol. 53, no. 4, pp. 549–554, 1988. View at Publisher · View at Google Scholar · View at Scopus
  77. T. Deramaudt and A. K. Rustgi, “Mutant KRAS in the initiation of pancreatic cancer,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1756, no. 2, pp. 97–101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. U.S. Food and Drug Administration, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?start_search=1&PMANumber=P140023.
  79. U.S._Food_and_Drug_Administration, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?start_search=1&PMANumber=P110027.
  80. D. Gonzalez De Castro, B. Angulo, B. Gomez et al., “A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens,” British Journal of Cancer, vol. 107, no. 2, pp. 345–351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. Roche Diagnostics, cobas® KRAS Mutation Test, 2012, http://www.accessdata.fda.gov/cdrh_docs/pdf14/P140023c.pdf.
  82. Qiagen, THERASCREEN® KRAS RGQ PCR, 2011, https://www.qiagen.com/us/landing-pages/therascreen-kras-test-usa-subgroups/.
  83. Qiagen, THERASCREEN® KRAS PYRO, 2010, https://www.qiagen.com/at/resources/resourcedetail?id=359d918e-6d54-4645-898f-f1846af9f18b&lang=en.
  84. Qiagen, RAS EXTENSION PYRO V2, 2016, https://www.qiagen.com/us/shop/detection-solutions/personalized-healthcare/ras-ext-pyro-kit-row/#resources.
  85. B. Bournet, C. Buscail, F. Muscari, P. Cordelier, and L. Buscail, “Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: hopes and realities,” European Journal of Cancer, vol. 54, pp. 75–83, 2016. View at Publisher · View at Google Scholar · View at Scopus
  86. E. Yonish-Rouach, D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren, “Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6,” Nature, vol. 352, no. 6333, pp. 345–347, 1991. View at Publisher · View at Google Scholar · View at Scopus
  87. D. Li, K. Xie, R. Wolff, and J. L. Abbruzzese, “Pancreatic cancer,” The Lancet, vol. 363, no. 9414, pp. 1049–1057, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. R. H. Hruban, C. Iacobuzio-Donahue, R. E. Wilentz, M. Goggins, and S. E. Kern, “Molecular pathology of pancreatic cancer,” Cancer Journal, vol. 7, no. 4, pp. 251–258, 2001. View at Google Scholar · View at Scopus
  89. K. Wada, “p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 9, no. 1, pp. 76–85, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. S. T. Glenn, C. A. Jones, S. Sexton et al., “Conditional deletion of p53 and Rb in the renin-expressing compartment of the pancreas leads to a highly penetrant metastatic pancreatic neuroendocrine carcinoma,” Oncogene, vol. 33, no. 50, pp. 5706–5715, 2014. View at Publisher · View at Google Scholar · View at Scopus
  91. B. Kong, T. Cheng, C. Qian et al., “Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma,” Molecular Cancer, vol. 14, no. 1, article 212, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. P. S. Moore, B. Sipos, S. Orlandini et al., “Genetic profile of 22 pancreatic carcinoma cell lines: analysis of K-ras, p53, p16 and DPC4/Smad4,” Virchows Archiv, vol. 439, no. 6, pp. 798–802, 2001. View at Publisher · View at Google Scholar · View at Scopus
  93. Y. Nio, M. Dong, K. Uegaki et al., “Comparative significance of p53 and WAF/1-P21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas,” Pancreas, vol. 18, no. 2, pp. 117–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Scholzen and J. Gerdes, “The Ki-67 protein: from the known and the unknown,” Journal of Cellular Physiology, vol. 182, no. 3, pp. 311–322, 2000. View at Publisher · View at Google Scholar · View at Scopus
  95. R. J. Bold, S. Virudachalam, and D. J. McConkey, “BCL2 expression correlates with metastatic potential in pancreatic cancer cell lines,” Cancer, vol. 92, no. 5, pp. 1122–1129, 2001. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Wu, C. Min, X. Wang et al., “Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells,” Cancer Research, vol. 67, no. 13, pp. 6278–6285, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Marx, “A challenge to p16 gene as a major tumor suppressor,” Science, vol. 264, no. 5167, article 1846, 1994. View at Publisher · View at Google Scholar · View at Scopus
  98. L. Bonetta, “Tumor-suppressor genes. Open questions on p16,” Nature, vol. 370, no. 6486, p. 180, 1994. View at Publisher · View at Google Scholar · View at Scopus
  99. C. Caldas, S. A. Hahn, L. T. de Costa et al., “Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma,” Nature Genetics, vol. 8, no. 1, pp. 27–32, 1994. View at Publisher · View at Google Scholar
  100. E. K. Duff and A. R. Clarke, “Smad4 (DPC4)—a potent tumour suppressor?” British Journal of Cancer, vol. 78, no. 12, pp. 1615–1619, 1998. View at Publisher · View at Google Scholar · View at Scopus
  101. S. A. Hahn, M. Schutte, A. T. M. Shamsul Hoque et al., “DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1,” Science, vol. 271, no. 5247, pp. 350–353, 1996. View at Publisher · View at Google Scholar · View at Scopus
  102. D. Maurice, C. E. Pierreux, M. Howell, R. E. Wilentz, M. J. Owen, and C. S. Hill, “Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability,” The Journal of Biological Chemistry, vol. 276, no. 46, pp. 43175–43181, 2001. View at Publisher · View at Google Scholar · View at Scopus
  103. H. Lodish, A. Berk, S. L. Zipursky, P. Matsudaira, D. Baltimore, and J. Darnell, Molecular Cell Biology, Section 24.4 Mutations Causing Loss of Cell-Cycle Control, W H Freeman, New York, NY, USA, 4th edition, 2000.
  104. Z.-H. Tang, S.-Q. Zou, Y.-H. Hao et al., “The relationship between loss expression of DPC4/Smad4 gene and carcinogenesis of pancreatobiliary carcinoma,” Hepatobiliary and Pancreatic Diseases International, vol. 1, no. 4, pp. 624–629, 2002. View at Google Scholar · View at Scopus
  105. M. Schutte, L. T. da Costa, S. A. Hahn et al., “Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 13, pp. 5950–5954, 1995. View at Publisher · View at Google Scholar · View at Scopus
  106. C. Abaji, I. Cousineau, and A. Belmaaza, “BRCA2 regulates homologous recombination in response to DNA damage: implications for genome stability and carcinogenesis,” Cancer Research, vol. 65, no. 10, pp. 4117–4125, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. M.-C. King, J. H. Marks, and J. B. Mandell, “Breast and Ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2,” Science, vol. 302, no. 5645, pp. 643–646, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. J. P. Struewing, P. Hartge, S. Wacholder et al., “The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews,” The New England Journal of Medicine, vol. 336, no. 20, pp. 1401–1408, 1997. View at Publisher · View at Google Scholar · View at Scopus
  109. S. A. Hahn, B. Greenhalf, I. Ellis et al., “BRCA2 germline mutations in familial pancreatic carcinoma,” Journal of the National Cancer Institute, vol. 95, no. 3, pp. 214–221, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Goggins, M. Sehutte, J. Lu et al., “Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas,” Cancer Research, vol. 56, no. 23, pp. 5360–5364, 1996. View at Google Scholar · View at Scopus
  111. M. Goggins, R. H. Hruban, and S. E. Kern, “BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications,” The American Journal of Pathology, vol. 156, no. 5, pp. 1767–1771, 2000. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Rowley, A. Ohashi, G. Mondal et al., “Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice,” Gastroenterology, vol. 140, no. 4, pp. 1303–1313, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. F. Skoulidis, L. D. Cassidy, V. Pisupati et al., “Germline Brca2 heterozygosity promotes KrasG12D -Driven carcinogenesis in a murine model of familial pancreatic cancer,” Cancer Cell, vol. 18, no. 5, pp. 499–509, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. S. Morinaga, Y. Nakamura, Y. Atsumi et al., “Locked nucleic acid in situ hybridization analysis of MicroRNA-21 predicts clinical outcome in patients after resection for pancreatic cancer treated with adjuvant gemcitabine monotherapy,” Anticancer Research, vol. 36, no. 3, pp. 1083–1088, 2016. View at Google Scholar
  115. X. Wei, W. Wang, L. Wang et al., “MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4,” Cancer Medicine, vol. 5, no. 4, pp. 693–702, 2016. View at Publisher · View at Google Scholar
  116. M. Gironella, M. Seux, M.-J. Xie et al., “Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 41, pp. 16170–16175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. W. Pang, J. Su, Y. Wang et al., “Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts,” Cancer Science, vol. 106, no. 10, pp. 1362–1369, 2015. View at Publisher · View at Google Scholar · View at Scopus
  118. Q. Ji, X. Hao, M. Zhang et al., “MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells,” PLoS ONE, vol. 4, no. 8, Article ID e6816, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. F. Jiao, H. Hu, C. Yuan et al., “Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth, migration and invasion in pancreatic cancer,” Oncology Reports, vol. 32, no. 6, pp. 2485–2492, 2014. View at Publisher · View at Google Scholar · View at Scopus
  120. F. Jiao, H. Hu, T. Han et al., “Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells,” International Journal of Molecular Sciences, vol. 16, no. 4, pp. 6677–6693, 2015. View at Publisher · View at Google Scholar · View at Scopus
  121. X. Lu, Y. Fang, Z. Wang et al., “Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6,” Cell and Tissue Research, vol. 354, no. 3, pp. 891–896, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. N. A. Schultz, C. Dehlendorff, B. V. Jensen et al., “MicroRNA biomarkers in whole blood for detection of pancreatic cancer,” The Journal of the American Medical Association, vol. 311, no. 4, pp. 392–404, 2014. View at Publisher · View at Google Scholar · View at Scopus
  123. S. Lust, B. Vanhoecke, M. Van Gele et al., “Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia,” Anticancer Research, vol. 29, no. 10, pp. 3797–3805, 2009. View at Google Scholar · View at Scopus
  124. S. Grant, “Enhancing proteotoxic stress as an anticancer strategy,” Oncotarget, vol. 2, no. 4, pp. 284–286, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. P. Workman and F. E. Davies, “A stressful life (or death): combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability,” Oncotarget, vol. 2, no. 4, pp. 277–280, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. X. Chen, J. Shen, and R. Prywes, “The luminal domain of ATF6 senses endoplasmic reticulum (ER) stress and causes translocation of ATF6 from the er to the Golgi,” The Journal of Biological Chemistry, vol. 277, no. 15, pp. 13045–13052, 2002. View at Publisher · View at Google Scholar · View at Scopus
  127. Y. Adachi, K. Yamamoto, T. Okada, H. Yoshida, A. Harada, and K. Mori, “ATF6 is a transcription factor specializing in the regulation of quality control proteins in the endoplasmic reticulum,” Cell Structure and Function, vol. 33, no. 1, pp. 75–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. V. M. Parmar and M. Schröder, “Sensing endoplasmic reticulum stress,” Advances in Experimental Medicine and Biology, vol. 738, pp. 153–168, 2012. View at Publisher · View at Google Scholar · View at Scopus
  129. J. M. Winter, C. J. Yeo, and J. R. Brody, “Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer,” Journal of Surgical Oncology, vol. 107, no. 1, pp. 15–22, 2013. View at Publisher · View at Google Scholar · View at Scopus
  130. A. S. Lee, “GRP78 induction in cancer: therapeutic and prognostic implications,” Cancer Research, vol. 67, no. 8, pp. 3496–3499, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. J. B. Gifford, W. Huang, A. E. Zeleniak et al., “Expression of GRP78, master regulator of the unfolded protein response, increases chemoresistance in pancreatic ductal adenocarcinoma,” Molecular Cancer Therapeutics, vol. 15, no. 5, pp. 1043–1052, 2016. View at Publisher · View at Google Scholar
  132. R. Kalluri and R. A. Weinberg, “The basics of epithelial-mesenchymal transition,” The Journal of Clinical Investigation, vol. 119, no. 6, pp. 1420–1428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. Y. Masugi, K. Yamazaki, T. Hibi, K. Aiura, Y. Kitagawa, and M. Sakamoto, “Solitary cell infiltration is a novel indicator of poor prognosis and epithelial-mesenchymal transition in pancreatic cancer,” Human Pathology, vol. 41, no. 8, pp. 1061–1068, 2010. View at Publisher · View at Google Scholar · View at Scopus
  134. A. D. Rhim, E. T. Mirek, N. M. Aiello et al., “EMT and dissemination precede pancreatic tumor formation,” Cell, vol. 148, no. 1-2, pp. 349–361, 2012. View at Publisher · View at Google Scholar · View at Scopus
  135. B. Hotz, M. Arndt, S. Dullat, S. Bhargava, H.-J. Buhr, and H. G. Hotz, “Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer,” Clinical Cancer Research, vol. 13, no. 16, pp. 4769–4776, 2007. View at Publisher · View at Google Scholar · View at Scopus
  136. S. Guaita, I. Puig, C. Francí et al., “Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression,” The Journal of Biological Chemistry, vol. 277, no. 42, pp. 39209–39216, 2002. View at Publisher · View at Google Scholar · View at Scopus
  137. J. Yang, S. A. Mani, J. L. Donaher et al., “Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis,” Cell, vol. 117, no. 7, pp. 927–939, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. X. Zheng, J. L. Carstens, J. Kim et al., “Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer,” Nature, vol. 527, no. 7579, pp. 525–530, 2015. View at Publisher · View at Google Scholar · View at Scopus
  139. T. Arumugam, V. Ramachandran, K. F. Fournier et al., “Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer,” Cancer Research, vol. 69, no. 14, pp. 5820–5828, 2009. View at Publisher · View at Google Scholar · View at Scopus
  140. K. Zhang, X. Jiao, X. Liu et al., “Knockdown of snail sensitizes pancreatic cancer cells to chemotherapeutic agents and irradiation,” International Journal of Molecular Sciences, vol. 11, no. 12, pp. 4891–4904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  141. T. Yin, C. Wang, T. Liu, G. Zhao, Y. Zha, and M. Yang, “Expression of snail in pancreatic cancer promotes metastasis and chemoresistance,” Journal of Surgical Research, vol. 141, no. 2, pp. 196–203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. Z. Wang, Y. Li, D. Kong et al., “Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway,” Cancer Research, vol. 69, no. 6, pp. 2400–2407, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. M. Leader, M. Collins, J. Patel, and K. Henry, “Vimentin: an evaluation of its role as a tumour marker,” Histopathology, vol. 11, no. 1, pp. 63–72, 1987. View at Google Scholar
  144. M. M. Javle, J. F. Gibbs, K. K. Iwata et al., “Epithelial-Mesenchymal Transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer,” Annals of Surgical Oncology, vol. 14, no. 12, pp. 3527–3533, 2007. View at Publisher · View at Google Scholar · View at Scopus
  145. Y.-E. Joo, J.-S. Rew, C.-S. Park, and S.-J. Kim, “Expression of E-cadherin, alpha- and beta-catenins in patients with pancreatic adenocarcinoma,” Pancreatology, vol. 2, no. 2, pp. 129–137, 2002. View at Publisher · View at Google Scholar · View at Scopus
  146. G. Klöppel, O. Basturk, A. M. Schlitter, B. Konukiewitz, and I. Esposito, “Intraductal neoplasms of the pancreas,” Seminars in Diagnostic Pathology, vol. 31, no. 6, pp. 452–466, 2014. View at Publisher · View at Google Scholar · View at Scopus
  147. M. I. Canto, F. Harinck, R. H. Hruban et al., “International cancer of the pancreas screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer,” Gut, vol. 62, no. 3, pp. 339–347, 2013. View at Publisher · View at Google Scholar · View at Scopus
  148. A. C. Berger, M. Garcia Jr., J. P. Hoffman et al., “Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704,” Journal of Clinical Oncology, vol. 26, no. 36, pp. 5918–5922, 2008. View at Publisher · View at Google Scholar · View at Scopus
  149. M. J. Ferri, M. Saez, J. Figueras et al., “Improved pancreatic adenocarcinoma diagnosis in jaundiced and non-jaundiced pancreatic adenocarcinoma patients through the combination of routine clinical markers associated to pancreatic adenocarcinoma pathophysiology,” PLoS ONE, vol. 11, no. 1, Article ID e0147214, 2016. View at Publisher · View at Google Scholar